📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
50 announcements match the current filters (relevance ≥ 5).
Shareholders Approve Fundraise via QIP with 99.97% Majority
Gujarat Themis Biosyn Limited (GUJTHEM) has received shareholder approval to raise funds through a Qualified Institutions Placement (QIP). The special resolution was passed with an overwhelming 99.9762% majority of the 7.94 crore votes polled. This capital raise is intended to support the company's strategic growth plan, which includes doubling fermentation capacity from 216 MT to 432 MT by FY26 and expanding into higher-value APIs. While the specific fundraise amount was not disclosed in this filing, the mandate allows the board to proceed with the capital infusion.
Confidence: HIGH
What changedShareholders have officially authorized the company to raise capital through a QIP, providing the board with a formal mandate to issue new equity shares to institutional investors.
Why it mattersThis fundraise is critical for financing the company's expansion strategy, which aims to increase total operating income to over INR 250 Cr (a 66% increase) and reduce reliance on a narrow product range through forward integration into APIs like Rifapentine.
Votes in favor (%): 99.9762%Total votes polled: 7,94,96,307Promoter votes in favor: 7,65,57,741Target capacity expansion: 432 MTTarget Operating Income: >INR 250 Cr
📅 Short termThe stock may see positive sentiment as the shareholder approval clears a major regulatory hurdle for the company's growth financing.
📈 Long termSuccessful capital raising and subsequent capacity doubling to 432 MT by FY26 could structurally re-rate the business, provided it manages its high client concentration (98% revenue from two clients).
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High client concentration (Lupin and Optrix account for 98% of sales)
- Execution risk in doubling fermentation capacity by FY26
Key Highlights
99.9762% of total votes cast in favor of the QIP fundraise resolution
100% support from the Promoter and Promoter Group with 7,65,57,741 votes in favor
98.5444% support from Public Institutions for the special resolution
Total of 7,94,96,307 votes polled across all shareholder categories
Resolution passed via Postal Ballot through e-voting as per the notice dated June 6, 2026
👀 What to Watch
Investors should monitor subsequent filings for the specific QIP floor price and the total quantum of capital to be raised. The key execution milestone to watch is the deployment of these funds toward the 100% fermentation capacity expansion scheduled for completion by FY26.
Shareholders Approve Fundraise via Qualified Institutions Placement (QIP)
Shareholders of Gujarat Themis Biosyn have approved a special resolution to raise capital through a Qualified Institutions Placement (QIP). The resolution received overwhelming support with 99.97% of votes cast in favor. This capital raise is intended to support the company's strategic goal of doubling fermentation capacity from 216 MT to 432 MT by FY26. While the specific fundraise amount was not disclosed in this filing, the approval is a critical step for financing its expansion into higher-value APIs.
Confidence: HIGH
What changedShareholders have officially authorized the board to issue equity shares to institutional investors, clearing the path for a QIP fundraise.
Why it mattersThis provides the financial means to execute a 100% capacity expansion and forward integration into APIs like Rifapentine, which are central to the company's growth strategy.
Votes in favor: 99.9762%Total votes polled: 7,94,96,307Target capacity expansion: 432 MTCurrent capacity: 216 MT
📅 Short termThe approval removes regulatory uncertainty regarding the company's ability to raise capital, which may be viewed positively by the market in the coming weeks.
📈 Long termThe fundraise is structurally significant as it fuels the doubling of production capacity and entry into higher-margin API segments by FY26.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High customer concentration (98% revenue from 2 clients)
Key Highlights
99.9762% of total votes cast were in favor of the QIP fundraise resolution
Promoter group cast 7,65,57,741 votes, all 100% in favor of the resolution
Total of 7,94,96,307 votes were polled during the postal ballot process
The fundraise supports the company's target to exceed INR 250 Cr in Total Operating Income
Capacity expansion from 216 MT to 432 MT is expected to be operational by end of FY26
👀 What to Watch
Investors should monitor subsequent filings for the specific QIP floor price and the total quantum of funds to be raised. The execution timeline of the fermentation capacity doubling will be the primary driver of long-term value.
99.98% Shareholder Approval for Fundraise via Qualified Institutions Placement (QIP)
Shareholders of Gujarat Themis Biosyn have approved a special resolution to raise funds through a Qualified Institutions Placement (QIP). The proposal received overwhelming support with 99.9762% of votes cast in favor, representing 72.96% of the total share capital. This capital raise is intended to support the company's strategic goal of doubling fermentation capacity from 216 MT to 432 MT by FY26. While the specific fundraise amount was not disclosed in this voting report, the approval is a critical step for the company's expansion into higher-value APIs.
Confidence: HIGH
What changedShareholders have officially authorized the company to raise capital through a QIP, clearing the regulatory path for institutional fund infusion.
Why it mattersThe fundraise is essential for financing the company's 100% capacity expansion and its transition into a higher-value API manufacturer, aiming for a revenue target exceeding Rs 250 Cr.
Votes in favor: 99.9762%Total shares: 108,965,265Voter turnout: 72.9556%Promoter support: 100%Planned capacity expansion: 100% (to 432 MT)
📅 Short termPositive sentiment expected as the company secures shareholder backing for growth capital; focus will now shift to institutional demand and pricing of the QIP.
📈 Long termStructurally significant if the capital is used to successfully double capacity and diversify the product mix, potentially reducing the current 98% revenue concentration from two clients.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High client concentration (98% revenue from two clients)
- Execution risk in doubling fermentation capacity
Key Highlights
Special resolution for QIP fundraise passed with 99.9762% majority in favor
Total of 79,477,366 votes cast in favor of the resolution out of 79,496,307 polled
Promoter group holding 77,218,083 shares voted 100% in favor of the proposal
Overall voter turnout stood at 72.9556% of the total 108,965,265 shares
Fundraise supports the planned 100% capacity expansion to 432 MT by FY26
👀 What to Watch
Monitor upcoming board announcements regarding the QIP floor price and the total quantum of funds to be raised. Track the deployment of these funds toward the fermentation capacity expansion and the stabilization of the new API unit.
99.98% Shareholder Approval for Fundraise via QIP
Gujarat Themis Biosyn Limited (GUJTHEM) has received overwhelming shareholder approval to raise funds through a Qualified Institutions Placement (QIP). The special resolution saw 99.9762% of the 7.95 crore votes cast in favor, including 100% support from the promoter group. This capital infusion is intended to support the company's strategic goal of doubling its fermentation capacity from 216 MT to 432 MT by FY26. The approval marks a critical step in financing the company's transition into higher-value APIs like Rifapentine.
Confidence: HIGH
What changedShareholders have officially authorized the company to raise capital through a QIP, transitioning the proposal into an actionable corporate event.
Why it mattersThis fundraise is essential for GUJTHEM to achieve its target of doubling capacity and reaching a Total Operating Income exceeding INR 250 Cr. It provides the financial runway for forward integration into the API market, reducing reliance on intermediates.
Approval Percentage: 99.9762%Total Votes Polled: 7,94,96,307Promoter Votes in Favor: 7,65,57,741Target Capacity Expansion: 432 MTCurrent Capacity: 216 MT
📅 Short termThe successful vote is likely to be viewed positively by the market as it clears the path for capital infusion; focus will now shift to the QIP pricing and participant list.
📈 Long termThe fundraise is structurally significant as it facilitates a 100% capacity increase and diversification into higher-margin APIs, which are expected to drive the next phase of revenue growth.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing retail shareholders
- High client concentration (98% of revenue from two clients)
- Execution risk associated with doubling fermentation capacity
Key Highlights
99.9762% of total votes (7,94,77,366 votes) were cast in favor of the QIP fundraise resolution.
Promoter group, holding 7.72 crore shares, voted 100% in favor of the proposal.
Public institutional investors showed 98.54% support with 12.61 lakh votes in favor.
The fundraise supports the planned 100% capacity expansion from 216 MT to 432 MT.
Total votes polled represented 72.95% of the total 10.89 crore outstanding shares.
👀 What to Watch
Investors should monitor subsequent board announcements regarding the specific QIP floor price and the total quantum of capital to be raised. The execution timeline for the 432 MT capacity expansion remains the primary long-term performance indicator.
GUJTHEM to Acquire Sanofi Portfolio for €158M and MicroBiopharm Japan (INR 561 Cr Revenue)
Gujarat Themis Biosyn (GTBL) has announced two transformative acquisitions: Sanofi’s anti-TB portfolio for €158 million and MicroBiopharm Japan (MBJ) with FY26 revenues of JPY 9.5 Bn (~INR 561.82 Cr). These acquisitions represent a massive scale-up, as the combined target revenues are approximately 6.7x GTBL's FY26 revenue of INR 165.82 Cr. Additionally, the company has doubled its fermentation capacity to 990 KL in FY26 and completed forward integration into APIs. While growth prospects are significant, the €158 million deal value is nearly 4.8x the company's FY26 net worth of INR 287.77 Cr, indicating a major funding requirement.
Confidence: HIGH
What changedGTBL is transitioning from a domestic fermentation intermediate manufacturer into a global CDMO and branded pharmaceutical platform through two large-scale international acquisitions.
Why it mattersThe acquisitions provide immediate access to regulated markets (Europe, Japan) and high-value therapeutic areas like oncology and biologics, potentially re-rating the company from a small-cap supplier to a global player.
Sanofi Portfolio Deal Value: €158 millionMBJ FY26 Revenue: INR 561.82 CrGTBL FY26 Revenue: INR 165.82 CrCombined Target Revenue vs GTBL FY26: ~670%Sanofi Deal vs FY26 Net Worth: ~486%Installed Fermentation Capacity: 990 KL
📅 Short termThe market is likely to react positively to the massive expansion in scale and global footprint, though details on funding the €158m acquisition will be a key focus.
📈 Long termIf successfully integrated, these acquisitions structurally transform GTBL into a diversified global pharma entity with proprietary technology in fermentation and biologics.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant funding requirement for €158m deal relative to net worth
- High execution risk in integrating Japanese and European operations
- Current high customer concentration (98% of revenue from two clients)
Key Highlights
Acquisition of Sanofi's 13 anti-TB and anti-infective brands for €158 million, covering 59 countries
Acquisition of MicroBiopharm Japan (MBJ) adding JPY 9.5 Bn (~INR 561.82 Cr) in revenue and 3 manufacturing plants
Annual fermentation capacity increased by 120% from 450 KL in FY25 to 990 KL in FY26
Maintained high operational efficiency with an EBITDA margin of 45.55% on FY26 revenue of INR 165.82 Cr
Forward integration completed for Rifapentine and Rifamycin APIs, moving up the value chain from intermediates
👀 What to Watch
Monitor the regulatory approval timeline for both acquisitions and the specific financing structure (debt vs. equity) for the €158 million Sanofi deal. Watch for the successful integration of MBJ's advanced biotech capabilities like ADCs and Plasmids into GTBL's existing fermentation platform.
Gujarat Themis Biosyn Initiates ₹90.24 Crore Arbitration Against Optimus Drugs
Gujarat Themis Biosyn Limited (GTBL) has initiated arbitration proceedings against Optimus Drugs Private Limited for the wrongful termination of a supply agreement. The company is seeking a total recovery of approximately ₹90.24 crores, primarily driven by a ₹75 crore claim for breach of 'Take-or-Pay' obligations. Additionally, the company is claiming ₹15 crores in damages and ₹23.81 lakhs for interest on delayed payments. As GTBL is the claimant, the management does not expect any negative financial implications or penalties from this proceeding.
Key Highlights
Initiated arbitration against Optimus Drugs Private Limited for breach of contract terms.
Claiming ₹75.00 crore in break fees due to violation of mandatory 'Take-or-Pay' purchase obligations.
Seeking ₹15.00 crore towards general damages and financial losses resulting from the termination.
Additional claim of ₹23.81 lakh for interest on delayed payments plus ongoing interest.
Management confirms no expected financial liability as the company is the party seeking recovery.
👀 What to Watch
Investors should view this as a potential long-term cash flow catalyst, though arbitration outcomes can take significant time to materialize. Monitor future disclosures for the tribunal's interim orders or final settlement terms.
Gujarat Themis Biosyn Promoter to Acquire 2.38% Stake via Inter-Se Transfer Worth Rs 100 Cr
Sachin D. Patel, a promoter of Gujarat Themis Biosyn Limited, has announced an intention to acquire up to 26,00,000 equity shares of the company, representing up to a 2.38% stake. The shares will be acquired from another promoter group entity, Themis Medicare Limited, via an inter-se transfer. The proposed transaction is valued at up to Rs. 100 crore and is scheduled to take place between June 30, 2026, and July 3, 2026. The acquisition price is set at Rs. 400.45 per share, which is a premium to the 60-day volume-weighted average market price of Rs. 369.15.
Key Highlights
Proposed acquisition of up to 26,00,000 equity shares representing a 2.38% stake in Gujarat Themis Biosyn.
Inter-se transfer between promoter group entities: Sachin D. Patel (Acquirer) and Themis Medicare Limited (Seller).
Transaction value is estimated up to Rs. 100 crore at a proposed price of Rs. 400.45 per share.
Post-transaction, Themis Medicare's stake will decrease from 23.19% to 20.81%, while Sachin D. Patel's stake will rise to 2.38%.
👀 What to Watch
This is an inter-se transfer within the promoter group and does not alter the overall promoter holding or trigger an open offer. Investors should treat this as a neutral liquidity realignment among promoters and continue to monitor the company's operational performance.
Gujarat Themis Biosyn Incorporates Step-down Subsidiary in Ireland
Gujarat Themis Biosyn Limited has successfully incorporated a new step-down subsidiary, Themis Biosyn Private Limited, in Ireland as of June 16, 2026. The new entity is a 100% subsidiary of Themis Biosyn Ireland Private Limited, which is already part of the company's group structure. With an initial share capital of 100 Euro, this move signals the company's strategic intent to expand its footprint in the international pharmaceutical market.
Key Highlights
Incorporation of Themis Biosyn Private Limited in Ireland on June 16, 2026.
The entity is a 100% step-down subsidiary of Gujarat Themis Biosyn Limited.
Initial share capital for the new Irish entity is 100 Euro.
The subsidiary will operate within the Pharmaceutical Industry, aligning with the parent's core business.
The move follows the regulatory framework of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should view this as a long-term positive for international expansion, though immediate financial impact will be negligible given the nominal initial capital. Watch for future announcements regarding specific operational mandates or manufacturing/distribution licenses obtained by this Irish unit.
Gujarat Themis Biosyn to Seek Approval for Rs 1,000 Crore Fundraise via QIP
Gujarat Themis Biosyn Limited (GUJTHEM) has issued a postal ballot notice to seek shareholder approval for raising up to Rs 1,000 crore through a Qualified Institutions Placement (QIP). The fundraise may involve equity shares, warrants, or convertible debentures issued to eligible institutional buyers. The remote e-voting period for this special resolution is scheduled from June 9, 2026, to July 8, 2026. This significant capital infusion is likely intended to support the company's growth initiatives and strengthen its balance sheet.
Key Highlights
Proposed fundraise of up to Rs 1,000 crore through QIP of equity shares or convertible securities.
Shareholders' approval sought via postal ballot with e-voting concluding on July 8, 2026.
Pricing will follow SEBI ICDR regulations with a potential discount of up to 5% on the floor price.
The company may issue warrants or debentures with a maximum tenure of 60 months.
The results of the postal ballot will be declared by July 10, 2026.
👀 What to Watch
Investors should monitor the specific end-use of the funds and the potential equity dilution once the QIP price and number of shares are finalized.
GUJTHEM Board Approves Fundraising of up to ₹1,000 Crores via QIP and Preferential Issue
Gujarat Themis Biosyn Limited has announced a major capital raising plan involving up to ₹1,000 Crores through a Qualified Institutions Placement (QIP). The board also approved a preferential issue of equity shares or warrants to non-promoter investors, with specific details to be finalized by a dedicated Fund-Raising Committee. These initiatives are subject to shareholder and regulatory approvals. The substantial fundraise suggests potential expansion or debt restructuring plans for the company.
Key Highlights
Approved raising of funds aggregating up to ₹1,000 Crores through Qualified Institutions Placement (QIP).
Authorized a preferential issue of equity shares to non-promoters in one or more tranches.
The Fund-Raising Committee will determine the final number of securities and the issue price for the preferential allotment.
The capital raise is subject to the approval of the company's members and necessary regulatory/statutory bodies.
👀 What to Watch
Investors should watch for the specific pricing of the QIP and the identity of the preferential allottees, as these will indicate institutional confidence. While the fundraise is positive for growth, shareholders should be mindful of the potential equity dilution resulting from these issuances.
GUJTHEM Shareholders Approve Increased Borrowing and Investment Limits Despite Institutional Dissent
Gujarat Themis Biosyn Limited (GUJTHEM) has successfully passed two special resolutions via postal ballot with over 98% majority. The resolutions authorize the company to increase borrowing limits and create charges on assets, as well as expand limits for loans, guarantees, and investments in other entities. While the resolutions passed due to strong promoter support, public institutional investors overwhelmingly voted against both proposals, with over 99.9% of their cast votes opposing the changes.
Key Highlights
Resolution to increase borrowing limits under Section 180(1)(c) passed with 98.39% of total votes in favor.
Resolution to approve limits for loans, guarantees, and investments passed with 98.38% favor.
Significant institutional resistance observed, with public institutions casting 1,277,290 votes (99.95%) against both resolutions.
Promoter group, holding 77.2 million shares, voted 100% in favor of the proposals.
Total voter turnout for the postal ballot was approximately 72.8% of the 108.96 million total shares.
👀 What to Watch
Investors should exercise caution and monitor the company's future capital allocation and debt-raising activities, as the near-unanimous institutional opposition suggests concerns regarding governance or potential di-worsification.
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary in Ireland with €100,000 Capital
Gujarat Themis Biosyn Limited has successfully incorporated a new wholly owned subsidiary, Themis Biosyn Ireland Private Limited, in Ireland on May 29, 2026. The new entity is established within the pharmaceutical industry with an initial share capital of 1,00,000 Euro. This strategic move signifies the company's intent to expand its international footprint and operational presence in the European market. The parent company maintains 100% shareholding and control over the new subsidiary.
Key Highlights
Incorporated a 100% Wholly Owned Subsidiary (WOS) named Themis Biosyn Ireland Private Limited in Ireland.
The subsidiary has an initial share capital of 1,00,000 Euro.
The entity will operate within the Pharmaceutical Industry, aligned with the parent company's core business.
Official date of incorporation and business registration was May 29, 2026.
👀 What to Watch
Investors should view this as a positive step toward global expansion and monitor future updates regarding the subsidiary's specific operational role and revenue contributions. Watch for management commentary on how this Irish base will facilitate entry into European pharmaceutical markets.
Gujarat Themis Q4 Revenue Up 17%; Announces Transformative ₹1,300 Cr Japan Acquisition
Gujarat Themis Biosyn (GTBL) reported Q4 FY26 revenue of ₹44.23 Cr, up 17.22% YoY, driven by robust sales volumes. The company announced two massive acquisitions: 13 brands from Sanofi for EUR 158 Mn and MicroBiopharm Japan for approximately ₹1,300 Cr, which are significantly larger than GTBL's current annual revenue of ₹165.82 Cr. While Q4 PAT fell 9.22% to ₹10.89 Cr due to higher interest and depreciation from ongoing capex, EBITDA margins remained strong at 43.77%. These acquisitions mark a strategic shift towards becoming a global fermentation-based CDMO with expanded therapeutic coverage.
Key Highlights
Q4 FY26 Revenue increased 17.22% YoY to ₹44.23 Cr; EBITDA rose 20.71% to ₹19.36 Cr.
Acquiring MicroBiopharm Japan for ~₹1,300 Cr, adding advanced biotech platforms and Top 6 global pharma customers.
Acquiring 13 Sanofi brands for EUR 158 Mn, adding EUR 62 Mn in revenue and access to 55+ countries.
FY26 PAT stood at ₹46.68 Cr, a slight decline of 4.29% YoY due to expansion-related depreciation and interest.
R&D investment reached 9% of topline in FY26, supporting the move into API and CDMO segments.
👀 What to Watch
The acquisitions are game-changers but will significantly increase debt and integration risk; long-term investors should focus on the CDMO transition. Monitor the funding mix and regulatory approvals for these large-scale deals as they will redefine the company's scale.
Gujarat Themis Biosyn Recommends Re 0.67 Dividend and Approves Preferential Share Issue
Gujarat Themis Biosyn has announced its audited financial results for the year ended March 31, 2026, alongside a final dividend recommendation of Re 0.67 per share. The company is also initiating a fundraise through a preferential issue of equity shares to non-promoters, signaling potential growth or expansion plans. A dedicated Preferential Issue Committee has been formed to finalize the terms, including the issue price and the number of securities to be issued. The total dividend payout is expected to be approximately Rs 7.30 crore, pending shareholder approval.
Key Highlights
Recommended a final dividend of Re 0.67 per equity share (67% of face value) for FY 2025-26.
Total dividend payout aggregates to Rs 7,30,06,728 subject to shareholder approval.
Approved a proposal for preferential issue of equity shares/warrants to non-promoters.
Constituted a Preferential Issue Committee to finalize pricing and allotment terms.
Re-appointed M/s. Raja Dutta & Co. as Cost Auditor for the Financial Year 2026-27.
👀 What to Watch
Investors should look out for the specific pricing and investor names for the preferential issue as it will impact equity dilution and growth prospects. The dividend provides a steady return, but the capital raise is the primary catalyst for future valuation.
Gujarat Themis Biosyn to Acquire Japan's MicroBiopharm for ~INR 1,300 Crore
Gujarat Themis Biosyn Limited (GTBL) has announced the 100% acquisition of MicroBiopharm Japan (MBJ) for JPY 21.5 billion (approximately INR 1,300 crore). MBJ is a fermentation-based CDMO with estimated FY26 revenues of JPY 9.5 billion (INR 570 crore) and three FDA/PMDA approved manufacturing plants. The acquisition, funded through a mix of debt and equity, is expected to be EPS accretive and will transform GTBL into a globally integrated CDMO with advanced capabilities in ADC conjugation and Plasmid DNA. The transaction is expected to close by Q2 FY2027, subject to regulatory approvals.
Key Highlights
Acquisition of 100% equity in MicroBiopharm Japan for JPY 21.5 Billion (~INR 1,300 Crore)
MBJ reports FY26E revenue of JPY 9.5 Billion (~INR 570 Crore) with 40% revenue from outside Japan
Acquisition includes 3 GMP-compliant plants with US FDA and PMDA approvals
Transaction expected to be EPS accretive and close by Q2 FY2027
Enables entry into high-tech segments like ADC conjugation, Plasmid DNA, and precision fermentation
👀 What to Watch
This is a transformative acquisition that significantly scales GTBL's operations and technological capabilities. Investors should monitor the final debt-equity funding ratio and the company's ability to integrate the Japanese operations to realize projected synergies.
Gujarat Themis Biosyn to Acquire Japan's MBJ for INR 1,300 Crores
Gujarat Themis Biosyn (GTBL) has signed a definitive agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores (JPY 21.5 billion). MBJ is a specialized fermentation-based CDMO with an estimated FY26 revenue of INR 570 crores and expertise in oncology, peptides, and advanced modalities like ADCs. The acquisition, expected to close in Q2FY27, will be funded through a mix of debt and equity and is projected to be EPS accretive. This strategic move transforms GTBL from an intermediates manufacturer into a globally integrated, technology-driven CDMO platform.
Key Highlights
Acquisition of 100% equity in MicroBiopharm Japan for JPY 21.5 billion (approx. INR 1,300 crores)
MBJ recorded an estimated revenue of JPY 9.5 billion (approx. INR 570 crores) for FY26E
Gains access to advanced technologies including P450 enzyme library, Plasmid DNA, and ADC conjugation
Acquisition includes two FDA and PMDA audited manufacturing sites in Japan, enhancing global regulatory reach
Management expects the transaction to be EPS accretive with a closing target of Q2FY27
👀 What to Watch
This is a transformative acquisition that significantly scales GTBL's revenue and technological capabilities; investors should monitor the final debt-equity mix used for funding. The entry into high-margin CDMO services and regulated markets like Japan and the US makes this a strong long-term growth catalyst.
Gujarat Themis Biosyn to Acquire Japan's MicroBiopharm for INR 1,300 Crores
Gujarat Themis Biosyn Limited (GTBL) has entered into a definitive agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores. MBJ is a specialized pharmaceutical firm with estimated FY26 revenues of INR 570 crores, focusing on microbial fermentation and CDMO services. This acquisition is transformational, shifting GTBL from an intermediates manufacturer to a technology-driven CDMO platform with capabilities in oncology and biotechnology. The transaction is expected to close in Q2 FY2027 and will be funded through a mix of debt and equity.
Key Highlights
Acquisition of 100% equity in MicroBiopharm Japan for JPY 21.5 billion (approx. INR 1,300 crores)
MBJ reported estimated FY26 revenue of INR 570 crores, significantly scaling GTBL's consolidated topline
Expands portfolio into high-value segments including oncology APIs, plasmid DNA, and ADC conjugation
Strategic shift towards becoming a global CDMO platform with advanced biotechnology capabilities
Transaction completion targeted for Q2 FY2027, subject to Japanese regulatory approvals
👀 What to Watch
This is a major growth milestone that elevates GTBL's technological profile and market reach; investors should monitor the specific debt-equity funding ratio and the subsequent integration of the Japanese operations.
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary 'Themis Biosyn Japan Limited' in Japan
Gujarat Themis Biosyn Limited has announced the successful incorporation of a new wholly owned subsidiary in Japan, named Themis Biosyn Japan Limited. The subsidiary was officially incorporated on May 19, 2026, and the company received the Certificate of Registration on May 20, 2026. This strategic move marks the company's entry into the Japanese market, potentially opening new revenue streams for its biotechnology and pharmaceutical products. Investors should note this as a key step in the company's international expansion strategy.
Key Highlights
Incorporation of a 100% wholly owned subsidiary in Japan.
New entity named Themis Biosyn Japan Limited.
Official date of incorporation recorded as May 19, 2026.
Certificate of Registration received by the parent company on May 20, 2026.
Move signifies strategic intent to expand global footprint in the pharmaceutical sector.
👀 What to Watch
Investors should monitor future disclosures regarding the specific business activities and capital expenditure planned for the Japanese subsidiary. This expansion is a positive long-term indicator of the company's growth ambitions beyond the Indian market.
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary in Japan with 1M Yen Capital
Gujarat Themis Biosyn Limited has successfully incorporated a wholly owned subsidiary, Themis Biosyn Japan Limited, in Japan on May 19, 2026. The new entity is established with an initial share capital of 1,000,000 Yen and will operate within the pharmaceutical industry. This move marks a strategic international expansion for the company, aiming to establish a direct presence in the Japanese market. While the initial investment is modest, it signals management's intent to grow its global footprint and potentially explore new regulatory or commercial opportunities abroad.
Key Highlights
Incorporated a 100% wholly owned subsidiary named Themis Biosyn Japan Limited on May 19, 2026.
The subsidiary is established with a share capital of 1,000,000 Yen (approximately ₹5.3 lakhs).
The entity will focus on the Pharmaceutical Industry, aligning with the parent company's core business.
The incorporation follows compliance with Regulation 30 of SEBI Listing Regulations 2015.
👀 What to Watch
Investors should view this as a positive long-term strategic move into a major global pharmaceutical market. Monitor future quarterly updates for specific business activities or contracts originating from this Japanese subsidiary.
Gujarat Themis Biosyn Seeks Approval to Raise Borrowing & Investment Limits to ₹3,500 Crores
Gujarat Themis Biosyn Limited has issued a postal ballot notice seeking shareholder approval for a significant increase in its financial headroom. The company proposes to raise its borrowing limits to ₹3,500 Crores, allowing for various debt instruments including term loans, NCDs, and external commercial borrowings. Simultaneously, it is seeking a ₹3,500 Crore limit for providing loans, guarantees, or making investments in other corporate bodies. These moves suggest the management is preparing for substantial capital expenditure or strategic inorganic growth opportunities.
Key Highlights
Proposed increase in borrowing limits to a maximum of ₹3,500 Crores under Section 180(1)(c).
Request for authorization to create charges or mortgages on company assets up to the ₹3,500 Crore limit.
Proposed limit for loans, guarantees, and investments in other entities set at ₹3,500 Crores under Section 186.
Remote e-voting period is scheduled from May 6, 2026, to June 4, 2026.
The results of the postal ballot are expected to be declared by June 8, 2026.
👀 What to Watch
Investors should monitor the company's subsequent announcements for specific project details or acquisition targets that necessitate such high financial limits. While the increased limits provide flexibility, actual debt utilization and the quality of new investments will be the primary drivers of long-term value.
